Metabolic Control of CD8 + T Cell Fate Decisions and Antitumor Immunity
Trends in Molecular Medicine, ISSN: 1471-4914, Vol: 24, Issue: 1, Page: 30-48
2018
- 169Citations
- 264Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations169
- Citation Indexes167
- 167
- CrossRef149
- Patent Family Citations2
- Patent Families2
- Captures264
- Readers264
- 264
Review Description
CD8 + T cells are central players in controlling infections and cancer. Longevity, functionality, and metabolic fitness are critical determinants of T cell efficacy in cancer immunotherapy. Tumor-infiltrating CD8 + T cells undergo metabolic ‘exhaustion’ in the nutrient- and oxygen-deprived tumor microenvironment (TME). Thus, reprograming CD8 + T cell metabolism may provide important therapeutic strategies for cancer treatment. Indeed, the adoptive transfer of memory CD8 + T cells with sustained metabolic fitness may yield better antitumor protection in both mouse models and the clinic. Here, we discuss recent progress on how cellular metabolism is linked to CD8 + T cell fate decisions and on how metabolic intermediates can impact gene expression via modulation of the epigenome. We examine the feasibility of developing potential strategies to improve antitumor immunity through the modulation of T cell metabolic activity.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1471491417302058; http://dx.doi.org/10.1016/j.molmed.2017.11.005; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85039076774&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/29246759; https://linkinghub.elsevier.com/retrieve/pii/S1471491417302058; https://dx.doi.org/10.1016/j.molmed.2017.11.005
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know